MAPT and tauopathy: Given the known high levels of neuronal tau occurring in vivo in disease states and the low-level tau expressed from single-copy transgenic strains, the single-copy strategy appears to be poorly suited for modeling tauopathy but could be suitable for identifying genetic enhancers and pathways contributing to tau proteostasis.